Holen Sie sich die Stockscreener-App
16.34
0.91%
-0.15
Handel nachbörslich:
16.34
Schlusskurs vom Vortag:
$16.49
Offen:
$16.54
24-Stunden-Volumen:
314.91K
Relative Volume:
0.75
Marktkapitalisierung:
$5.79B
Einnahmen:
$5.10B
Nettoeinkommen (Verlust:
$-352.00M
KGV:
-16.04
EPS:
-1.0189
Netto-Cashflow:
$-66.14M
1W Leistung:
+7.08%
1M Leistung:
-4.22%
6M Leistung:
+9.74%
1J Leistung:
+34.93%
1-Tages-Spanne:
$16.22
$16.63
1-Wochen-Bereich:
$15.41
$16.89
52-Wochen-Spanne:
$10.45
$18.91
Bausch Lomb Corp Stock (BLCO) Company Profile
Firmenname
Bausch Lomb Corp
Sektor
Telefon
908-541-5456
Adresse
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, ALC, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
16.34 | 5.84B | 5.10B | -352.00M | -66.14M | -1.0189 |
ISRG
Intuitive Surgical Inc
|
452.58 | 160.56B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
155.32 | 43.95B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
74.63 | 36.34B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
43.88 | 35.94B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
224.93 | 32.65B | 5.40B | 1.49B | 1.78B | 10.12 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-10-01 | Eingeleitet | Goldman | Neutral |
| 2025-05-02 | Bestätigt | H.C. Wainwright | Buy |
| 2025-03-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-07-10 | Eingeleitet | Raymond James | Outperform |
| 2024-05-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-12 | Eingeleitet | Stifel | Hold |
| 2023-10-03 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-09 | Eingeleitet | Needham | Hold |
| 2022-12-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-06-24 | Eingeleitet | Evercore ISI | Outperform |
| 2022-06-06 | Eingeleitet | Citigroup | Buy |
| 2022-05-31 | Eingeleitet | Deutsche Bank | Hold |
| 2022-05-31 | Eingeleitet | Goldman | Neutral |
| 2022-05-31 | Eingeleitet | Guggenheim | Buy |
| 2022-05-31 | Eingeleitet | JP Morgan | Neutral |
| 2022-05-31 | Eingeleitet | Jefferies | Buy |
| 2022-05-31 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-05-11 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Bausch Lomb Corp Aktie (BLCO) Neueste Nachrichten
Dry eye and cataract data lead Bausch + Lomb's 45-study ASCRS lineup - Stock Titan
BLCO SEC FilingsBausch + Lomb Corporation 10-K, 10-Q, 8-K Forms - Stock Titan
Q4 Rundown: Bausch + Lomb (NYSE:BLCO) Vs Other Medical Devices & SuppliesSpecialty Stocks - Yahoo! Finance Canada
BLCO Stock Price, Quote & Chart | BAUSCH + LOMB CORP (NYSE:BLCO) - ChartMill
Bausch + Lomb Corporation (NYSE:BLCO) Receives Average Rating of "Hold" from Analysts - MarketBeat
Bausch + Lomb Corporation (BLCO) stock price, news, quote and history - Yahoo Finance Singapore
Should Positive ELIOS Glaucoma Trial Results Require Action From Bausch + Lomb (BLCO) Investors? - simplywall.st
Stocks in play: Bausch + Lomb Corporation - Yahoo! Finance Canada
Bausch + Lomb to webcast Q1 results and business update April 29 - Stock Titan
Bausch + Lomb Corp Stock: Eye Health Leader with Strong Product Portfolio and Growth Potential for I - AD HOC NEWS
Tudor Investment Corp ET AL Takes $2.25 Million Position in Bausch + Lomb Corporation $BLCO - MarketBeat
Bausch + Lomb Corp. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators - Markets Mojo
A Look At Bausch + Lomb (BLCO) Valuation After Recent Share Price Pullback - Yahoo Finance
Bausch And Lomb (NYSE:BLCO) Shares Draw Eyes Across Nyse Composite Today - Kalkine Media
3 Reasons BLCO is Risky and 1 Stock to Buy Instead - Yahoo Finance
A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story - Yahoo Finance
A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story - The Motley Fool
Goldman Sachs Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Maintains Target Price $19 - 富途牛牛
Bausch + Lomb Achieves Key Milestone in Glaucoma Treatment with ELIOS System - Intellectia AI
Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma - BioSpace
Bausch + Lomb reports positive glaucoma trial results for ELIOS - Investing.com
Glaucoma laser left 82% of patients medication-free in U.S. trial - Stock Titan
Bausch + Lomb Corp Stock (ISIN: CA07174N1090) Faces Headwinds Amid Vision Care Market Shifts and Deb - AD HOC NEWS
RBC reiterates Bausch & Lomb stock rating on DED rival delay - Investing.com Australia
Bausch + Lomb Corp. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
RBC reiterates Bausch & Lomb stock rating on DED rival delay By Investing.com - Investing.com South Africa
Bausch + Lomb Corp Stock (ISIN: CA07174N1090) Faces Headwinds Amid Vision Care Demand Slowdown and D - AD HOC NEWS
Eye Care Giant Posts $5.1 Billion in Revenue as One Investor Builds Major Position - AOL.com
Bausch + Lomb Corporation (NYSE:BLCO) Sees Large Decline in Short Interest - MarketBeat
Bausch + Lomb Corp Stock (ISIN: CA07174N1090) Faces Headwinds Amid Vision Care Demand Shifts - AD HOC NEWS
Is It Time To Reconsider Bausch + Lomb (BLCO) After Recent Share Price Weakness - Yahoo Finance
Bausch + Lomb Corporation $BLCO Shares Purchased by Compass Rose Asset Management LP - MarketBeat
Bausch + Lomb Corporation Investigated by the Portnoy Law Firm - globenewswire.com
Citi Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
Bausch & Lomb (BLCO) legal chief buys shares and receives 14,600 matching RSUs - Stock Titan
Bausch And Lomb (NYSE:BLCO) Glaucoma Moves Catch Market Eyes Nyse Composite Today - Kalkine Media
Bausch & Lomb (NYSE: BLCO) CFO buys 4,000 shares, gets 4,000 RSUs - Stock Titan
Bausch & Lomb (BLCO) CEO buys 14,700 shares and receives matching RSUs - Stock Titan
Bausch + Lomb Corporation - Baystreet.ca
Inside Bausch + Lomb’s glaucoma webinar on new treatments - Stock Titan
Assessing Bausch + Lomb (NYSE:BLCO) Valuation After Latest Revenue And Net Loss Update - Yahoo Finance
Short Covering: Will Bausch Lomb Corporation outperform its industry peersJuly 2025 Levels & Fast Moving Market Watchlists - baoquankhu1.vn
Integra LifeSciences, GE HealthCare, Bausch + Lomb, ICU Medical, and Universal Health Services Shares Are Falling, What You Need To Know - Finviz
Insider Buying: Ross Thomas W. Sr. Acquires Shares in Bausch & L - GuruFocus
Director adds BLCO stake with 4,500-share buy and 4,500 RSUs grant - Stock Titan
Potential Bausch + Lomb Separation Reframes Bausch Health - simplywall.st
Insider Buying: Eduardo Alfonso Acquires Shares of Bausch & Lomb Corp (BLCO) - GuruFocus
[Form 4] Bausch & Lomb Corp Insider Trading Activity - Stock Titan
Bausch & Lomb (NYSE: BLCO) director buys shares, gets RSUs - Stock Titan
BLCO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bausch & Lomb (NYSE: BLCO) SVP disposes shares for taxes - Stock Titan
Finanzdaten der Bausch Lomb Corp-Aktie (BLCO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.50%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):